Tags

Type your tag names separated by a space and hit enter

Treatment of Peyronie's disease with intralesional verapamil injection.
J Urol. 1997 Oct; 158(4):1395-9.JU

Abstract

PURPOSE

In a previous study, 83% of 14 patients noted that their symptoms of Peyronie's disease had arrested or improved after intralesional injection of verapamil. This nonrandomized, prospective study further investigates the use of verapamil in a larger, thoroughly characterized patient population.

MATERIALS AND METHODS

Forty-six men began treatment; 38 completed the study. Using a multiple puncture technique, 10 mg. of verapamil diluted to 10 cc were distributed throughout the plaque every 2 weeks for a total of 12 injections. Response to treatment was evaluated through subjective and objective measurements of pain, plaque size, deformity, duration of disease and sexual function, and with the Kelami classification system based on plaque size and curvature.

RESULTS

Pain resolved in 97% of the patients who presented with pain after a mean of 2.5 injections. After therapy, 76% reported a subjective decrease in curvature, 9.5% noted an increase and 14.5% remained unchanged. Of the treated patients 72% reported an improvement in the ability to engage in coitus. Objective measurements demonstrated that curvature was decreased in 54% of the patients, increased in 11% and remained unchanged in 34%. There were no substantial differences in response to treatment based on duration of disease or within the 3 Kelami classification groups. Other than transient post-injection ecchymosis, there were no significant acute or chronic side effects.

CONCLUSIONS

Verapamil injection therapy resulted in a reduction of pain in 97% of the patients, an improvement in sexual function in 72%, a reduction of deformity in 86%, an improvement in distal rigidity in 93% and an objective reduction of curvature in 54%. Further studies are required to determine the effectiveness of this nontoxic, inexpensive, nonsurgical approach to Peyronie's disease.

Authors+Show Affiliations

Department of Urology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA.

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

9302129

Citation

Levine, L A.. "Treatment of Peyronie's Disease With Intralesional Verapamil Injection." The Journal of Urology, vol. 158, no. 4, 1997, pp. 1395-9.
Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol. 1997;158(4):1395-9.
Levine, L. A. (1997). Treatment of Peyronie's disease with intralesional verapamil injection. The Journal of Urology, 158(4), 1395-9.
Levine LA. Treatment of Peyronie's Disease With Intralesional Verapamil Injection. J Urol. 1997;158(4):1395-9. PubMed PMID: 9302129.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of Peyronie's disease with intralesional verapamil injection. A1 - Levine,L A, PY - 1997/9/25/pubmed PY - 1997/9/25/medline PY - 1997/9/25/entrez SP - 1395 EP - 9 JF - The Journal of urology JO - J Urol VL - 158 IS - 4 N2 - PURPOSE: In a previous study, 83% of 14 patients noted that their symptoms of Peyronie's disease had arrested or improved after intralesional injection of verapamil. This nonrandomized, prospective study further investigates the use of verapamil in a larger, thoroughly characterized patient population. MATERIALS AND METHODS: Forty-six men began treatment; 38 completed the study. Using a multiple puncture technique, 10 mg. of verapamil diluted to 10 cc were distributed throughout the plaque every 2 weeks for a total of 12 injections. Response to treatment was evaluated through subjective and objective measurements of pain, plaque size, deformity, duration of disease and sexual function, and with the Kelami classification system based on plaque size and curvature. RESULTS: Pain resolved in 97% of the patients who presented with pain after a mean of 2.5 injections. After therapy, 76% reported a subjective decrease in curvature, 9.5% noted an increase and 14.5% remained unchanged. Of the treated patients 72% reported an improvement in the ability to engage in coitus. Objective measurements demonstrated that curvature was decreased in 54% of the patients, increased in 11% and remained unchanged in 34%. There were no substantial differences in response to treatment based on duration of disease or within the 3 Kelami classification groups. Other than transient post-injection ecchymosis, there were no significant acute or chronic side effects. CONCLUSIONS: Verapamil injection therapy resulted in a reduction of pain in 97% of the patients, an improvement in sexual function in 72%, a reduction of deformity in 86%, an improvement in distal rigidity in 93% and an objective reduction of curvature in 54%. Further studies are required to determine the effectiveness of this nontoxic, inexpensive, nonsurgical approach to Peyronie's disease. SN - 0022-5347 UR - https://wwww.unboundmedicine.com/medline/citation/9302129/Treatment_of_Peyronie's_disease_with_intralesional_verapamil_injection_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-5347(01)64224-1 DB - PRIME DP - Unbound Medicine ER -